Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions
DRUG

ELA026

Multiple doses of ELA026

Trial Locations (22)

10032

RECRUITING

Columbia University, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19107

RECRUITING

Thomas Jefferson University, Philadelphia

20007

ACTIVE_NOT_RECRUITING

MedStar Georgetown, Washington D.C.

33701

RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

35233

RECRUITING

University of Alabama at Birmingham School of Medicine, Birmingham

77030

RECRUITING

Texas Children's Hospital, Houston

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

85016

ACTIVE_NOT_RECRUITING

Phoenix Children's Hospital, Phoenix

90095

ACTIVE_NOT_RECRUITING

University of California, Los Angeles, Los Angeles

Unknown

WITHDRAWN

Medizinische Universität Innsbruck, Innsbruck

COMPLETED

Medical University of Vienna, Vienna

COMPLETED

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan

WITHDRAWN

Bambino Gesu' Roma, Roma

ACTIVE_NOT_RECRUITING

Amsterdam UMC, Amsterdam

ACTIVE_NOT_RECRUITING

Erasmus UMC, Rotterdam

WITHDRAWN

Hospital 12 de Octubre, Madrid, Madrid

COMPLETED

Hospital Ramon y Cajal, Madrid

WITHDRAWN

Hospital La Fe Valencia, Valencia

ACTIVE_NOT_RECRUITING

University College London Hospitals, London

07747

RECRUITING

Universitätsklinikum Jena, Jena

Sponsors
All Listed Sponsors
lead

Electra Therapeutics Inc.

INDUSTRY